After stopping a PPI, rebound acid hypersecretion can cause new heartburn and reflux symptoms, even in people who had none before.

Original statement

لكنّ المفتاح الذي يفسّر الإدمان الذي يصفه د. ضياء هو دراسة ريمر (Gastroenterology 2009): 120 متطوعاً صحيحاً تماماً، أُعطوا إيزوميبرازول 40 ملغ ثمانية أسابيع. بعد التوقف، 44% منهم ظهرت لديهم حرقة وارتداد لأول مرة في حياتهم، مقابل 15% للغفل. الدواء يخلق المرض الذي يدّعي علاجه. هذا هو الفخّ الذي يحذّر منه: ابدأ نكسيم لشكوى عابرة، فلا تستطيع التوقف.

not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.

Translation

After stopping a PPI, rebound acid hypersecretion can cause new heartburn and reflux symptoms, even in people who had none before.

Origin

Source status

Archive editors

Attribution

Archive editors (eltayebat.com); not verified as Elawady's own words

Origin

https://eltayebat.com/rule/acid-blockers/

Attribution uncertainty

Written by the archive operators; study selection is the archive's, not necessarily Elawady's.

Claimed mechanism

Prolonged acid suppression raises gastrin and parietal-cell mass; after withdrawal acid output transiently overshoots.

Claimed health effect

New or worse acid-related symptoms after stopping.

Population concerned

PPI users after withdrawal (shown in healthy volunteers).

Geographic restriction by Elawady

none found

Diverging source versions

Scientific assessment

Mostly true – Correct at its core, but with limitations or minor inaccuracies.

Certainty of evidence: moderate – Further research may still affect the assessment.

1. What was claimed?

Stopping PPIs causes rebound acid symptoms, even in healthy people.

2. What is demonstrably correct?

Correct. In Reimer 2009, 44% (26/59) of healthy volunteers who stopped 8 weeks of esomeprazole reported at least one relevant acid-related symptom in weeks 9–12 versus 15% (9/59) on placebo. AGA 2022 advises warning patients about transient rebound symptoms.

3. What is wrong or exaggerated?

The narrative's phrase 'for the first time in their lives' and the conclusion that the drug 'manufactures the disease' overstate a transient, mostly mild effect; weekly proportions fell to 21% (vs 2%) by week 12.

4. What remains unclear?

The clinical importance of rebound in patients with real reflux disease is unclear (studies were methodologically weak).

5. Which studies support it?

A-PPI-14; Lødrup 2013 (I-PPI-06); AGA 2022 BPA 8 (I-PPI-04).

6. Which studies contradict it?

Lødrup 2013: three studies in reflux patients found no sign of symptomatic rebound (but with methodological weaknesses).

7. What applies to Germany and Europe?

PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.

8. What is known about Egypt?

Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.

9. What practical conclusion is appropriate?

When a PPI is stopped, transient symptoms are expected and do not by themselves prove that the drug is needed; tapering or on-demand use can help (AGA 2022, Farrell 2017).

Assessment details

Rationale for certainty of evidence

One well-conducted double-blind RCT in 120 healthy volunteers plus a second volunteer study (systematic review: 44% symptoms up to 4 weeks after withdrawal); evidence in reflux patients is weak and inconsistent; AGA 2022 accepts transient rebound symptoms.

Source quality

RCT correctly cited by the archive.

Regional transferability

High.

Individual exceptions

Symptoms are usually mild to moderate and transient.

Regional scope of the claim

general (biological/medical)

Last reviewed

25 October 2026 provisional

In plain language

If you take a strong acid blocker for some weeks and then stop, the stomach can make more acid than usual for a while. A good trial in healthy volunteers showed that almost half had heartburn-type symptoms in the following weeks, compared with 15% on placebo. These symptoms are usually mild and pass.

Studies on this claim

Regional context

Germany / EU

PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.

Egypt

Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.

What applies in my country?

General scientific assessment

Mostly true Correct: rebound acid symptoms after stopping PPIs are real but usually mild and temporary.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

1. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy.. Reimer C et al.. Gastroenterology 2009 · PMID 19362552 · DOI 10.1053/j.gastro.2009.03.058
2. Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment.. Lødrup AB et al.. Scand J Gastroenterol 2013 · PMID 23311977 · DOI 10.3109/00365521.2012.746395
3. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.. Targownik LE et al.. Gastroenterology 2022 · PMID 35183361 · DOI 10.1053/j.gastro.2021.12.247